| Identification | Back Directory | [Name]
Sabatolimab | [CAS]
2252262-24-9 | [Synonyms]
Sabatolimab
Sabatolimab (anti-TIM-3)
Research Grade Sabatolimab(DHJ28402) |
| Hazard Information | Back Directory | [Uses]
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells[1]. | [target]
TIM-3 | [References]
[1] Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood?(2020) 136 (Supplement 1): 1–2. |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|